Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
Positive preliminary results support Viaskin Milk's potential as the first treatment for patients suffering from IgE-mediated cow's milk protein allergy (CMPA), an unmet medical need for which there are no approved therapies
A statistically significant desensitization to milk was observed in children ages two to 11 treated with Viaskin Milk 300 µg for 12 months
Company evaluating optimal dosing/patient population for future studies
MONTROUGE, February 26, 2018 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced preliminary results from Part B, or Phase II, of a Phase I/II study evaluating the efficacy and safety of three dose regimens of Viaskin Milk (150 µg, 300 µg, 500 µg) in 198 patients for the treatment of IgE-mediated cow's milk protein allergy (CMPA). The MILES (Milk Efficacy and Safety) study was designed to determine a safe and effective dose in two age groups: children ages two to 11 and adolescents ages 12 to 17.
To download the full version of the Press Release in English language, please click on the following link: PDF Version
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/df4594b4-8f4f-45e7-939d-26f615740953
